Cyteir Therapeutics is a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases. The company's initial approach takes advantage of the 'gain-of-function' from DNA damage overload to induce selective self-destruction of cells by targeting disease-induced RAD51 transport. Cyteir's lead molecules were initially discovered using the company's drug discovery platform, which enables identification of primary cells with tunable genetic constraints.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
03/08/18	$29,000,000	Series B	Celgene Corporation DROIA Oncology Ventures Lightstone Ventures Venrock	undisclosed
10/15/19	$40,200,000	Series B	Celgene Corporation DROIA Oncology Ventures Lightstone Ventures Novo Holdings Osage University Partners Venrock	undisclosed
02/11/21	$80,000,000	Series C	Acuta Capital Partners Ally Bridge Group Ample Plus Fund Avidity Partners CaaS Capital Management DROIA Oncology Ventures Janus Henderson Investors Lightstone Ventures Novo Holdings Osage University Partners RA Capital Management Venrock	undisclosed